

Patients Involved | Case Report

Advisory boards on psoriasis clinical trials

Novartis Advisory Board with Patient Organisations to address patient relevant endpoints in psoriasis clinical trials involved six National Psoriasis Patient Organisations representatives (Germany, Italy, France, Spain, Sweden and Switzerland) to discuss patient relevant endpoints in psoriasis clinical trials.



Who was involved?

Novartis Pharmaceuticals, patient organisations

Level of patient expertise

- Patients with personal disease experience
- Expert patients/patient advocates with good expertise on disease but little R&D experience
- Expert patients/patient advocates with good expertise on disease and good R&D experience

Benefits

- Patient relevant endpoints identified e.g. quality of life as primary secondary endpoint, efficacy and safety long term, rapidity for young patients.
- Psoriasis Area Severity Index (PASI) is not relevant for patients, important is location of plaques.
- Patient friendly materials and trained nurses to support treatment self-administration, compliance and trial participants' awareness of concomitant therapies are requested.

Challenges

- Find expert advocates with a specific knowledge in clinical trials.

Learnings

- Earlier start (Phase II and protocol design phase).
- Multi-stakeholders Advisory Board (with Key Opinion Leaders and/or payers).

